We are faced with a global pandemic of tuberculosis and new tools to control this disease are needed urgently. We believe that new and old optimized drugs are central to any control strategy and the fastest route to tuberculosis elimination.
Latest news
SUDOCU headline results presented at CROI
On Tuesday 20 February 2023 our PanACEA colleague Dr Norbert Heinrich presented the headline-results from the PanACEA SUDOCU study at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle – the largest and most important conference on HIV and related conditions such as tuberculosis. SUDOCU investigated safety and efficacy of varying doses of…
PanACEA & SimpliciTB Annual Meeting, Mangochi, Malawi, 20th-22nd September 2022
Finally, after 2 years due to COVID-19, the PanACEA and SimpliciTB family were reunited in Malawi, hosted by Dr Marriott Nliwasa, Kamuzu University of Health Sciences at Makokola Retreat, Mangochi. The hospitality and organisation of all of the teams made it a very successful and enjoyable meeting. PanACEA The first day started with a variety…
Read more PanACEA & SimpliciTB Annual Meeting, Mangochi, Malawi, 20th-22nd September 2022
STATUS update: SUDOCU completed recruitment!
The PanACEA SUDOCU study completed its recruitment: a total of 75 participants were randomized to 5 arms (15 participants each) with a wide range of sutezolid doses (from 0mg to 800mg BID given over three months). With this open-label, randomized, phase 2B, dose selection study (ClinicalTrials.gov identifier NCT03959566) we aim to describe the safety/tolerability-exposure relationship…
Shorter treatment may be possible with higher rifampicin doses
An interview with prof. dr. Martin Boeree A considerably higher dose of the anti-tuberculosis drug rifampicin has been found to be safe according to a recent publication by PanACEA. Higher dosing of rifampicin may lead to a shorter / more efficacious treatment for tuberculosis with less resistance development. With this finding PanACEA researchers complete a…
Read more Shorter treatment may be possible with higher rifampicin doses
Can Calculus Help Tuberculosis Treatment?
The St Andrews group’s most recent paper has been published as a perspective piece in the International Journal of Tuberculosis and Lung Disease.The collaboration between the Schools of Medicine, Applied Mathematics and Computer Science provides an overview of the different types of model that can be applied to tuberculosis clinical trials. Importantly, it provides a…